Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis. Issue 1 (January 2017)

• Record Type: Journal Article
• Authors: Dosoki, Heba; Stegemann, Agatha; Taha, Muna; Schnittler, Hans; Luger, Thomas A.; Schröder, Katrin; Distler, Jörg H. W.; Kerkhoff, Claus; Böhm, Markus
• Is Part Of: Experimental dermatology. Volume 26:Issue 1(2017)
• Page Start: 73
• Page End: 81
• Publication Date: 2017-01
• Subjects: collagen -- dermal fibroblasts -- fibrosis -- Myofibroblast -- NADPH; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.13180
• Languages: English
• ISSNs: 0906-6705

Abstract

Abstract: Although there is increasing evidence that oxidative stress is involved in collagen synthesis and myofibroblast activation, the NADPH oxidase (Nox) system is incompletely investigated in the context of human dermal fibroblasts (HDFs) and skin fibrosis. Using the pan‐Nox inhibitor diphenyleneiodonium (DPI) as an initial tool, we show that gene expression of collagen type I, α‐smooth muscle actin (α‐SMA) and fibronectin 1 is suppressed in HDFs. Detailed expression analysis of all Nox isoforms and adaptors revealed expression of RNA and protein expression of Nox4, p22 phox and Poldip2 but neither Nox1 nor Nox2. Nox4 could be immunolocalized to the endoplasmic reticulum. Importantly, TGF‐β1 had a dose‐ and time‐dependent upregulating effect on NADH activity and Nox4 gene expression in HDFs. Genetic silencing of Nox4 as demonstrated by siRNA in HDFs as well as in murine fibroblasts established from Nox4 knockout mice confirmed that TGF‐β1 ‐mediated collagen type I gene, α‐SMA and fibronectin 1 gene expressions were Nox4‐dependent. This TGF‐β1 effect was mediated by Smad3 as shown by in silico promoter analysis, pharmacological inhibition and gene silencing of Smad3. The relevance of these findings is highlighted in the bleomycin‐induced scleroderma mouse model. DPI treatment attenuated skin fibrosis and myofibroblast activation. Moreover, Nox4 knockdown by siRNA reduced skin collagen synthesis, α‐SMA and fibronectin 1 expression in vivo. Finally, analyses of HDFs from patients with systemic sclerosis confirmed the expression of Nox4 and its adaptors, whereas Nox1 and Nox2 were not detectable. Our findings indicate that Nox4 targeting is a promising future treatment for fibrotic skin diseases.